Comparison of 1.1 GBq and 2.2 GBq Activities in Patients with Low-Risk Differentiated Thyroid Cancer Requiring Postoperative 131I Administration: A Real Life Study
Abstract
:Simple Summary
Abstract
1. Introduction
2. Patients and Methods
2.1. Study Design, Subjects, and Data Collection
2.2. Patient Management, Response Assessment, and Follow-Up
2.3. Laboratory Tests
2.4. Imaging
3. Statistical Analysis
4. Results
5. Discussion
6. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Data Availability Statement
Acknowledgments
Conflicts of Interest
References
- Giovanella, L.; Deandreis, D.; Vrachims, A.; Campenni, A.; Ovcaricek, P.P. Molecular Imaging and Theragnostics of Thyroid Cancers. Cancers 2022, 14, 1272. [Google Scholar] [CrossRef] [PubMed]
- Campennì, A.; Ruggeri, R.M.; Siracusa, M.; Giacoppo, G.; Torre, F.L.; Saccomanno, A.; Alibrandi, A.; Dionigi, G.; Tuccari, G.; Baldari, S.; et al. Isthmus Topography Is a Risk Factor for Persistent Disease in Patients with Differentiated Thyroid Cancer. Eur. J. Endocrinol. 2021, 185, 397–404. [Google Scholar] [CrossRef] [PubMed]
- Lim, H.; Devesa, S.S.; Sosa, J.A.; Check, D.; Kitahara, C.M. Trends in Thyroid Cancer Incidence and Mortality in the United States, 1974–2013. JAMA 2017, 317, 1338–1348. [Google Scholar] [CrossRef] [PubMed]
- Davies, L.; Welch, H.G. Increasing Incidence of Thyroid Cancer in the United States, 1973–2002. JAMA 2006, 295, 2164–2167. [Google Scholar] [CrossRef]
- Horn-Ross, P.L.; Lichtensztajn, D.Y.; Clarke, C.A.; Dosiou, C.; Oakley-Girvan, I.; Reynolds, P.; Gomez, S.L.; Nelson, D.O. Continued Rapid Increase in Thyroid Cancer Incidence in California: Trends by Patient, Tumor, and Neighborhood Characteristics. Cancer Epidemiol. Biomark. Prev. 2014, 23, 1067–1079. [Google Scholar] [CrossRef]
- National Cancer Institute. Cancer Statistics Review, 1975–2018—SEER Statistics; National Cancer Institute: Bethesda, MD, USA, 2021.
- Maas, O.; Forrer, F.; Maas, M.; Panje, C.M.; Blautzik, J.; Brühlmeier, M.; Engel-Bicik, I.; Giovanella, L.; Haldemann, A.; Kamel, M.E.; et al. Variations in Radioiodine Ablation: Decision-Making after Total Thyroidectomy. Eur. J. Nucl. Med. Mol. Imaging 2020, 47, 554–560. [Google Scholar] [CrossRef]
- Haugen, B.R.; Alexander, E.K.; Bible, K.C.; Doherty, G.M.; Mandel, S.J.; Nikiforov, Y.E.; Pacini, F.; Randolph, G.W.; Sawka, A.M.; Schlumberger, M.; et al. 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 2016, 26, 1–133. [Google Scholar] [CrossRef]
- Campennì, A.; Barbaro, D.; Guzzo, M.; Capoccetti, F.; Giovanella, L. Personalized Management of Differentiated Thyroid Cancer in Real Life—Practical Guidance from a Multidisciplinary Panel of Experts. Endocrine 2020, 70, 280–291. [Google Scholar] [CrossRef]
- Verburg, F.A.; Aktolun, C.; Chiti, A.; Frangos, S.; Giovanella, L.; Hoffmann, M.; Iakovou, I.; Mihailovic, J.; Krause, B.J.; Langsteger, W.; et al. Why the European Association of Nuclear Medicine Has Declined to Endorse the 2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer. Eur. J. Nucl. Med. Mol. Imaging 2016, 43, 1001–1005. [Google Scholar] [CrossRef]
- Michael Tuttle, R.; Ahuja, S.; Avram, A.M.; Bernet, V.J.; Bourguet, P.; Daniels, G.H.; Dillehay, G.; Draganescu, C.; Flux, G.; Führer, D.; et al. Controversies, Consensus, and Collaboration in the Use of 131 I Therapy in Differentiated Thyroid Cancer: A Joint Statement from the American Thyroid Association, the European Association of Nuclear Medicine, the Society of Nuclear Medicine and Molecular. Thyroid 2019, 29, 461–470. [Google Scholar] [CrossRef]
- Pacini, F.; Fuhrer, D.; Elisei, R.; Handkiewicz-Junak, D.; Leboulleux, S.; Luster, M.; Schlumberger, M.; Smit, J.W. 2022 ETA Consensus Statement: What Are the Indications for Post-Surgical Radioiodine Therapy in Differentiated Thyroid Cancer? Eur. Thyroid. J. 2022, 11, e210046. [Google Scholar] [CrossRef] [PubMed]
- Avram, A.M.; Giovanella, L.; Greenspan, B.; Lawson, S.A.; Luster, M.; Van Nostrand, D.; Peacock, J.G.; Ovčariček, P.P.; Silberstein, E.; Tulchinsky, M.; et al. SNMMI Procedure Standard/EANM Practice Guideline for Nuclear Medicine Evaluation and Therapy of Differentiated Thyroid Cancer: Abbreviated Version. J. Nucl. Med. 2022, 63, 15N–35N. [Google Scholar] [PubMed]
- Filetti, S.; Durante, C.; Hartl, D.; Leboulleux, S.; Locati, L.D.; Newbold, K.; Papotti, M.G.; Berruti, A. Thyroid Cancer: ESMO Clinical Practice Guidelines for Diagnosis, Treatment and Follow-Up. Ann. Oncol. 2019, 30, 1856–1883. [Google Scholar] [CrossRef] [PubMed]
- Schlumberger, M.; Leboulleux, S.; Catargi, B.; Deandreis, D.; Zerdoud, S.; Bardet, S.; Rusu, D.; Godbert, Y.; Buffet, C.; Schvartz, C.; et al. Outcome after Ablation in Patients with Low-Risk Thyroid Cancer (ESTIMABL1): 5-Year Follow-up Results of a Randomised, Phase 3, Equivalence Trial. Lancet Diabetes Endocrinol. 2018, 6, 618–626. [Google Scholar] [CrossRef]
- Mallick, U.; Harmer, C.; Yap, B.; Wadsley, J.; Clarke, S.; Moss, L.; Nicol, A.; Clark, P.M.; Farnell, K.; McCready, R.; et al. Ablation with Low-Dose Radioiodine and Thyrotropin Alfa in Thyroid Cancer. N. Engl. J. Med. 2012, 366, 1674–1685. [Google Scholar] [CrossRef]
- Campennì, A.; Giovanella, L.; Pignata, S.A.; Violi, M.A.; Siracusa, M.; Alibrandi, A.; Moleti, M.; Amato, E.; Ruggeri, R.M.; Vermiglio, F.; et al. Thyroid Remnant Ablation in Differentiated Thyroid Cancer: Searching for the Most Effective Radioiodine Activity and Stimulation Strategy in a Real-Life Scenario. Nucl. Med. Commun. 2015, 36, 1100–1106. [Google Scholar] [CrossRef]
- Du, P.; Jiao, X.; Zhou, Y.; Li, Y.; Kang, S.; Zhang, D.; Zhang, J.; Lv, L. Low versus High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Meta-Analysis of Randomized Controlled Trials. Endocrine 2015, 48, 96–105. [Google Scholar] [CrossRef]
- Eilsberger, F.; Tuttle, R.M.; Librizzi, D.; Pfestroff, A.; Luster, M.; Verburg, F.A. Perioperative Diagnostics of Patients Referred for Radioiodine Therapy of Differentiated Thyroid Carcinoma: Referral Center Experience in an Iodine-Insufficient Country. Endocrine 2021, 72, 721–726. [Google Scholar] [CrossRef]
- Campennì, A.; Ruggeri, R.M.; Siracusa, M.; Comis, A.D.; Romano, D.; Vento, A.; Lanzafame, H.; Capoccetti, F.; Alibrandi, A.; Baldari, S.; et al. Early Preablation RhTSH-Stimulated Thyroglobulin Predicts Outcome of Differentiated Thyroid Cancer (DTC) Patients. Eur. J. Nucl. Med. Mol. Imaging 2021, 48, 2466–2475. [Google Scholar] [CrossRef]
- Torres, M.S.T.; Ramirez, L.; Simkin, P.H.; Braverman, L.E.; Emerson, C.H. Effect of Various Doses of Recombinant Human Thyrotropin on the Thyroid Radioactive Iodine Uptake and Serum Levels of Thyroid Hormones and Thyroglobulin in Normal Subjects. J. Clin. Endocrinol. Metab. 2001, 86, 1660–1664. [Google Scholar] [CrossRef]
- Campennì, A.; Giovanella, L.; Siracusa, M.; Stipo, M.E.; Alibrandi, A.; Cucinotta, M.; Ruggeri, R.M.; Baldari, S. Is Malignant Nodule Topography an Additional Risk Factor for Metastatic Disease in Low-Risk Differentiated Thyroid Cancer? Thyroid 2014, 24, 1607–1611. [Google Scholar] [CrossRef] [PubMed]
- Campennì, A.; Giovanella, L.; Pignata, S.A.; Vento, A.; Alibrandi, A.; Sturiale, L.; Laudicella, R.; Comis, A.D.; Filice, R.; Giuffrida, G.; et al. Undetectable or Low (<1 Ng/Ml) Postsurgical Thyroglobulin Values Do Not Rule out Metastases in Early Stage Differentiated Thyroid Cancer Patients. Oncotarget 2018, 9, 17491–17500. [Google Scholar] [CrossRef] [PubMed]
- Campennì, A.; Vrachimis, A.; Siracusa, M.; Baldari, S.; Giovanella, L. Usefulness of 123I-Spect/Ct to Assess the Response to Initial Therapy in Differentiated Thyroid Cancer Patients. Endocrine 2021, 74, 193–196. [Google Scholar] [CrossRef] [PubMed]
- Ho, A.L. Moving toward a Better Understanding of Radioiodine Action. Endocrine 2013, 44, 553–554. [Google Scholar] [CrossRef]
- Schvartz, C.; Bonnetain, F.; Dabakuyo, S.; Gauthier, M.; Cueff, A.; Fieffe, S.; Pochart, J.M.; Cochet, I.; Crevisy, E.; Dalac, A.; et al. Impact on Overall Survival of Radioactive Iodine in Low-Risk Differentiated Thyroid Cancer Patients. J. Clin. Endocrinol. Metab. 2012, 97, 1526–1535. [Google Scholar] [CrossRef]
- Grazia Castagna, M.; Cevenini, G.; Theodoropoulou, A.; Maino, F.; Memmo, S.; Claudia, C.; Belardini, V.; Brianzoni, E.; Pacini, F. Post-Surgical Thyroid Ablation with Low or High Radioiodine Activities Results in Similar Outcomes in Intermediate Risk Differentiated Thyroid Cancer Patients. Eur. J. Endocrinol. 2013, 169, 23–29. [Google Scholar] [CrossRef]
- Mäenpää, H.O.; Heikkonen, J.; Vaalavirta, L.; Tenhunen, M.; Joensuu, H. Low vs. High Radioiodine Activity to Ablate the Thyroid after Thyroidectomy for Cancer: A Randomized Study. PLoS ONE 2008, 3, e1885. [Google Scholar] [CrossRef]
- Xing, M.; Haugen, B.R.; Schlumberger, M. Progress in Molecular-Based Management of Differentiated Thyroid Cancer. Lancet 2013, 381, 1058–1069. [Google Scholar] [CrossRef]
- Liu, R.; Bishop, J.; Zhu, G.; Zhang, T.; Ladenson, P.W.; Xing, M. Mortality Risk Stratification by Combining BRAF V600E and TERT Promoter Mutations in Papillary Thyroid Cancer: Genetic Duet of BRAF and TERT Promoter Mutations in Thyroid Cancer Mortality. JAMA Oncol. 2017, 3, 202–208. [Google Scholar] [CrossRef]
- Leboulleux, S.; Bournaud, C.; Chougnet, C.N.; Zerdoud, S.; Al Ghuzlan, A.; Catargi, B.; Do Cao, C.; Kelly, A.; Barge, M.-L.; Lacroix, L.; et al. Thyroidectomy without Radioiodine in Patients with Low-Risk Thyroid Cancer. N. Engl. J. Med. 2022, 386, 923–932. [Google Scholar] [CrossRef]
- Clerc, J.; Verburg, F.A.; Avram, A.M.; Giovanella, L.; Hindié, E.; Taïeb, D. Radioiodine Treatment after Surgery for Differentiated Thyroid Cancer: A Reasonable Option. Eur. J. Nucl. Med. Mol. Imaging 2017, 44, 918–925. [Google Scholar] [CrossRef] [PubMed]
- Clerc, J.; Bienvenu-Perrard, M.; Pichard De Malleray, C.; Dagousset, F.; Delbot, T.; Dreyfuss, M.; Groussin, L.; Marlowe, R.J.; Leger, F.A.; Chevalier, A. Outpatient Thyroid Remnant Ablation Using Repeated Low 131-Iodine Activities (740 MBq/20 MCix2) in Patients with Low-Risk Differentiated Thyroid Cancer. J. Clin. Endocrinol. Metab. 2012, 97, 871–880. [Google Scholar] [CrossRef] [PubMed]
- Song, X.; Meng, Z.; Jia, Q.; Zhang, L.; Xu, K.; Tan, J.; Zhang, G.; Zheng, W.; Li, X.; Zhang, J. Different Radioiodine Dose for Remnant Thyroid Ablation in Patients With Differentiated Thyroid Cancer: A Meta-Analysis. Clin. Nucl. Med. 2015, 40, 774–779. [Google Scholar] [CrossRef] [PubMed]
Total Sample (n = 299) | Low RAI Activity (n = 139) | Moderate RAI Activity (n = 160) | p-Value | ||||
---|---|---|---|---|---|---|---|
Gender, n (%) | |||||||
Male | 74 | (24.8) | 37 | (26.6) | 37 | (23.1) | 0.286 § |
Female | 225 | (75.3) | 102 | (73.4) | 123 | (76.9) | |
Age (years), median (min–max) | 51 | (18–88) | 49 | (23–79) | 52 | (18–88) | 0.067 * |
Size (mm), median (min–max) | 9 | (1–35) | 10 | (2–35) | 8 | (1–34) | 0.348 * |
Basal Tg (ng/mL), median (min–max) | 0.20 | (0.20–3.30) | 0.20 | (0.20–3.20) | 0.20 | (0.20–3.30) | 0.348 * |
Histology, n (%) | |||||||
PTC | 246 | (82.3) | 109 | (78.4) | 137 | (85.6) | 0.662 ç |
FTC | 47 | (15.7) | 25 | (18.0) | 22 | (13.8) | 0.084 ç |
HC | 6 | (2.0) | 5 | (3.6) | 1 | (0.6) | 0.088 ç |
Histotype, n (%) | |||||||
Nonaggressive # | 282 | (94.3) | 127 | (91.4) | 155 | (96.9) | 0.095 ç |
Aggressive ## | 17 | (5.7) | 12 | (8.6) | 5 | (3.1) | 0.085 ç |
Metastases pT-imaging, n (%) | |||||||
No | 246 | (82.3) | 117 | (84.2) | 129 | (80.6) | 0.444 ç |
Yes | 53 | (17.7) | 22 | (15.8) | 31 | (19.4) | 0.215 ç |
Low 131I Activity (n = 139) | Moderate 131I Activity (n = 160) | p-Value | |||
---|---|---|---|---|---|
ER, n (%) | 119 | (85.6) | 155 | (96.9) | 0.029 ç |
BIR, n (%) | 7 | (5.0) | 0 | (0.0) | 0.002 ç |
BIndR, n (%) | 10 | (7.2) | 3 | (1.8) | 0.046 ç |
SIR, n (%) | 3 | (2.2) | 2 | (1.3) | 0.654 ç |
Low RAI Activity (n = 22) | Moderate RAI Activity (n = 31) | p-Value | |||
---|---|---|---|---|---|
Gender, n (%) | |||||
Male | 7 | (31.8) | 6 | (19.4) | 0.236 § |
Female | 15 | (68.2) | 25 | (80.6) | |
Age (years), median (range) | 49 | (32–68) | 52 | (26–88) | 0.539 * |
Size (mm), median (range) | 8 | (2–24) | 10 | (2–21) | 0.589 * |
Basal Tg (ng/mL), median (range) | 0.2 | (0.2–3.2) | 0.3 | (0.2–3.3) | 0.247 * |
Histology, n (%) | |||||
PTC | 21 | (95.5) | 25 | (83.3) | 0.226 § |
FTC | 1 | (4.5) | 5 | (16.7) | |
Histotype, n (%) | |||||
No aggressive | 20 | (90.9) | 30 | (96.8) | 0.563 § |
Aggressive | 2 | (9.1) | 1 | (3.2) |
Overall Sample OR | Patients with Metastases OR | |
---|---|---|
Moderate 131I Activity | 5.1 *** (2.9) | 22.5 *** (17.4) |
Basal Tg (ng/mL) | 0.1 *** (0.1) | 0.2 (0.1) |
LR chi-square | 53.6 *** | 43.12 *** |
No. of patients | 299 | 53 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2023 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
Share and Cite
Campennì, A.; Ruggeri, R.M.; Garo, M.L.; Siracusa, M.; Restuccia, G.; Rappazzo, A.; Rosarno, H.; Nicocia, A.; Cardile, D.; Ovčariček, P.P.; et al. Comparison of 1.1 GBq and 2.2 GBq Activities in Patients with Low-Risk Differentiated Thyroid Cancer Requiring Postoperative 131I Administration: A Real Life Study. Cancers 2023, 15, 2416. https://doi.org/10.3390/cancers15092416
Campennì A, Ruggeri RM, Garo ML, Siracusa M, Restuccia G, Rappazzo A, Rosarno H, Nicocia A, Cardile D, Ovčariček PP, et al. Comparison of 1.1 GBq and 2.2 GBq Activities in Patients with Low-Risk Differentiated Thyroid Cancer Requiring Postoperative 131I Administration: A Real Life Study. Cancers. 2023; 15(9):2416. https://doi.org/10.3390/cancers15092416
Chicago/Turabian StyleCampennì, Alfredo, Rosaria Maddalena Ruggeri, Maria Luisa Garo, Massimiliano Siracusa, Giovanna Restuccia, Andrea Rappazzo, Helena Rosarno, Antonio Nicocia, Davide Cardile, Petra Petranović Ovčariček, and et al. 2023. "Comparison of 1.1 GBq and 2.2 GBq Activities in Patients with Low-Risk Differentiated Thyroid Cancer Requiring Postoperative 131I Administration: A Real Life Study" Cancers 15, no. 9: 2416. https://doi.org/10.3390/cancers15092416